Bookrunner on ProQR Therapeutics’ $50.0 Million Underwritten Registered Direct Offering

Oppenheimer & Co. Inc. acted as Bookrunner on ProQR Therapeutics’ $50.0 Million Underwritten Registered Direct Offering

ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR” or “Company”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, announced the pricing of its underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million.

Concurrently with the Offering, ProQR has entered into a share purchase agreement with Eli Lilly and Company (“Lilly”), one of its existing shareholders and a strategic partner, in a separately negotiated transaction pursuant to which ProQR agreed to offer and sell, and Lilly agreed to purchase, 5,100,780 ordinary shares, to permit Lilly to maintain its pro rata beneficial ownership, at the Offering Price, for total gross proceeds of approximately $9.2 million. The closing of the Offering is not contingent upon the closing of the concurrent private placement. The ordinary shares purchased in the concurrent private placement will not be subject to any underwriting discounts or commissions.

ProQR currently intends to use the net proceeds from the Offering and the concurrent private placement, together with its existing cash and cash equivalents, primarily to fund research and clinical development of its current or additional pipeline candidates and for working capital, capital expenditures and other general corporate purposes.

Healthcare Life Sciences Investment Banking